Results 21 to 30 of about 231,281 (308)

Drug interactions in COVID-19 treatment. Systematic review [PDF]

Farmacja Polska, 2022
The COVID-19 pandemic has driven the experimental, off-label treatments with co-administration of supportive therapies for many patients with severe infections and coexisting chronic conditions. This situation has inevitably led to polypharmacy, which is
Arkadiusz Adamiszak, Tomasz Torliński, Edmund Grześkowiak, Alicja Bartkowska-Śniatkowska, Agnieszka Bienert   +4 more
doaj   +1 more source

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea [PDF]

, 2023
Introduction Regdanvimab, a neutralising monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of coronavirus disease 2019 (COVID-19) in South Korea in 2021.
Jung, Nahyun, Jung, Yoobin, Kim, Jungok, Lee, Ji Yeon, Hwang, Chankyoung, Yu, Sungbong, Seo, Kwang Won, Kim, Sunghyun, Kim, Jin Yong, Song, EunHyang, Kym, Sungmin, Park, Sang Won, Lee, Yeonmi, Kwon, Ki Tae, Ahn, Keumyoung, Bu, Seon Hee, Cho, Seongcheol   +16 more
core   +1 more source

Reuse of drugs in the treatment of COVID-19

Research, Society and Development, 2022
After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then
Alessandra Isabô Neri, Lílian Carla Carneiro, Cristiene Costa Carneiro, Aroldo Vieira de Moraes Filho, Lee Chen-Chen   +4 more
openaire   +2 more sources

CSF3 Is a Potential Drug Target for the Treatment of COVID-19 [PDF]

Frontiers in Physiology, 2021
Coronavirus Disease 2019 (COVID-19) is an acute respiratory infectious disease that appeared at the end of 2019. As of July 2020, the cumulative number of infections and deaths have exceeded 15 million and 630,000, respectively. And new cases are increasing.
Chao Fang, Chao Fang, Jie Mei, Huixiang Tian, Yu-Ligh Liou, Dingchao Rong, Wei Zhang, Qianjin Liao, Nayiyuan Wu, Nayiyuan Wu   +9 more
openaire   +3 more sources

Viribus Unitis: Drug Combinations as a Treatment Against COVID-19

, 2020
The opportunities that may be provided by synergistic antiviral action of drugs for battling SARS-CoV2 are currently underestimated. Modern AI technologies realized as text, data, and knowledge mining and analytics tools provide the researchers with ...
Alexey, Zakharov, Eugene, Muratov
core   +2 more sources

Knowledge-Graph-Based Drug Repositioning against COVID-19 by Graph Convolutional Network with Attention Mechanism

Future Internet, 2021
The current global crisis caused by COVID-19 almost halted normal life in most parts of the world. Due to the long development cycle for new drugs, drug repositioning becomes an effective method of screening drugs for COVID-19. To find suitable drugs for
Mingxuan Che, Kui Yao, Chao Che, Zhangwei Cao, Fanchen Kong   +4 more
doaj   +1 more source

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions [PDF]

British Journal of Clinical Pharmacology, 2020
In a recent issue of Br J Clin Pharmacol Smith et al1 published an outstanding commentary titled ‘Dosing will be a key success factor in repurposing antivirals for Covid-19’. They highlighted that the success in our repurposing efforts will be dependent on ‘getting the dose right’ for drugs which have been developed for different indications and ...
Back, David, Marzolini, Catia, Hodge, Catherine, Marra, Fiona, Boyle, Alison, Gibbons, Sara, Burger, David, Khoo, Saye   +7 more
openaire   +8 more sources

Pentoxifylline: An Immunomodulatory Drug for the Treatment of COVID-19

Journal of Pure and Applied Microbiology, 2020
Rapidly spreading outbreak of the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is causing serious health concerns worldwide.
Hiren A. Dhameliya, Vasudev R. Thakkar, Gauravi N. Trivedi, Sureshkumar N. Mesara, R.B. Subramanian   +4 more
doaj   +1 more source

ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential

Pharmaceuticals, 2021
On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems, administrations, and treatment ingenuity across the world.
Subrata Deb, Anthony Allen Reeves, Robert Hopefl, Rebecca Bejusca   +3 more
doaj   +1 more source

Investigational antiviral drugs for the treatment of COVID-19 patients [PDF]

Archives of Virology, 2022
In the current pandemic of coronavirus disease 2019 (COVID-19), antiviral drugs are at the center of attention because of their critical role against severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2). In addition to designing new antivirals against SARS-COV-2, a drug repurposing strategy is a practical approach for treating COVID-19.
Samineh Beheshtirouy, Elnaz Khani, Sajad Khiali, Taher Entezari-Maleki   +3 more
openaire   +2 more sources